from:Challenges and new technologies in adoptive cell therapy
Zhang et al. Journal of Hematology & Oncology (2023) 16:97. https://doi.org/10.1186/s13045-023-01492-8
当前常见的过继性细胞疗法包括:
- 适应性免疫细胞(Adaptive immune cell)
-- TILs,Tumor-infiltrating lymphocytes,肿瘤浸润淋巴细胞
-- TCR-T,T-cell receptor–engineered/modified T-cell,T细胞受体嵌合T细胞
-- CAR-T,Chimeric antigen rerceptor T-cell,嵌合抗原受体T细胞
- 固有免疫细胞(Innate immune cell)
-- CAR-NK,CAR-natural killer
-- CAR-M,CAR-macrophage
-- CAR-γδT
-- CAR-NKT,CAR-natural killer T
Fig. 1 Summary of current adoptive cell therapies in cancer treatment.
- Th, helper T cell; 辅助性T细胞
- CTL, cytotoxic T lymphocyte; 细胞毒性T淋巴细胞;
- PBMC, peripheral blood mononuclear cell; 外周血单个核细胞;
- iPSC, induced pluripotent stem cell; 诱导多能干细胞;
- hESC, human embryonic stem cell; 人胚胎干细胞;
- UCB, umbilical cord blood; 脐带血;
- hPSC, human pluripotent stem cell; BM, bone marrow; 人多能干细胞hPSC;BM,骨髓;
- ADCC, antibody-dependent cell-mediated cytotoxicity; 抗体依赖性细胞介导的细胞毒性;
- CRS, cytokine release syndrome; 细胞因子释放综合征;
- ICANS, immune effector cell-associated neurotoxicity syndrome; 免疫效应细胞相关神经毒性综合征;
- GvHD, graft versus host disease; 移植物抗宿主病;
- MMP, matrix metalloproteinase; 基质金属蛋白酶;
- ECM, extracellular matrix; 细胞外基质;
- RV, retrovirus; 逆转录病毒;
- LV, lentivirus; 慢病毒;
- AdV, adenovirus 腺病毒
为帮助审核人员更快处理,请填写举报原因:
为帮助审核人员更快处理,请填写举报原因: